secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-07-14T10:30:09+00:00
Accession:  0001193125-26-302473
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero in-licenses SP001 anti-CD40L antibody from Innovent, secures $105M non-dilutive financing
--------------------------------------------------------------------------------

- In-licensed SP001 (anti-CD40L) from Innovent; Spero gets ex-China rights. Upfront $35M, milestones up to ~$1.05B, tiered royalties high single to mid-teen %.
- SP001 Phase 2-ready; Spero plans Phase 2 in IgG4-RD in Q2 2027. Innovent plans Phase 2 in SjD in China by early 2027.
- Secured $105M non-recourse notes from HCRx (KKR) at 10% interest, 9-year maturity, backed by Utebzi milestones/royalties from GSK.
- Cash runway extended into H2 2029; proceeds to fund SP001 development.
- Spero retains 35% of GSK proceeds after note repayment; HCRx gets 65% after note repayment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/0001193125-26-302473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-302473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer